MichaelSiavashKhodadoustMD

PubMed

• 1890 citations
  Profiling Tumor Infiltrating Immune Cells with CIBERSORT
  Binbin Chen, Michael S. Khodadoust, Chih Long Liu, Aaron M. Newman, Ash A. Alizadeh
  Methods in Molecular Biology. 2018-01-01
• 2142 citations
  Determining cell type abundance and expression from bulk tissues with digital cytometry.
  Aaron M. Newman, Chloé B. Steen, Chih Long Liu, Andrew J. Gentles, Aadel A. Chaudhuri
  Nature Biotechnology. 2019-05-06
• 7 citations
  A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.
  Jenna M Kastenschmidt, Joseph G Schroers-Martin, Brian J Sworder, Suhas Sureshchandra, Michael S Khodadoust
  Cell Stem Cell. 2024-03-07

Journal Articles

• Targeted Killing of TNFR2-Expressing Tumor Cells and Tregs by TNFR2 Antagonistic Antibodies in Advanced Sézary Syndrome  
  D L Faustman, Y H Kim, M Khodadoust, Nature
• Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study  
  Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
• IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 Study  
  Pierluigi Porcu, Basem William, Michael Khodadoust, European Journal of Cancer

Abstracts/Posters

• Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and N... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018